Roche Presents P-III (HAVEN 6) Study Results of Hemlibra (emicizumab) for Moderate or Mild Haemophilia A at ISTH 2022
- The primary analysis of the P-III (HAVEN 6) study evaluating the safety, efficacy, PK & PD of Hemlibra in 72 patients with mod. or mild haemophilia A without factor VIII inhibitors
- The results showed an effective bleed control & the therapy maintained low treated bleed rates, 66.7% of patients experienced no bleeds; no spontaneous bleeds (81.9%); no joint bleeds (88.9%), and model-based ABR remained low throughout the evaluation period at 0.9. The safety profile was consistent with findings across multiple subpopulations from prior (HAVEN) & (STASEY) studies with no new safety signals
- 1 patient experienced a grade one thromboembolic event unrelated to Hemlibra, no deaths or cases of thrombotic microangiopathy were reported
Ref: Roche | Image: Roche
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].